Navigation Links
Cord Blood America Announces 3rd Quarter and Nine Months 2012 Financial Results
Date:11/15/2012

LAS VEGAS, Nov. 15, 2012 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company") today announced financial results for the three and nine months periods ended September 30, 2012.

Third Quarter 2012 Highlights

  • Revenue increased 14% to $1.51 million from $1.33 million in the year ago period.
  • Recurring revenue increased 13% to $698,103.
  • Administrative and selling expenses decreased 14% to $1.09 million from $1.22 million in the year ago period.
  • The company reported EBITDA of $166,841 compared to a loss of $206,949 in the year ago period.
  • Nine-Months Ended September 30, 2012 Highlights

  • Revenue increase 18% to $4.64 million from $3.93 million in the year ago period.
  • Our cash position increased over 100% to $369,186.
  • Gross margin increased to 72.7% from 70.5% in the year ago period.
  • SG&A decreased 24% or $1.17 million to $3.64 million from $4.81 million.
  • For the second consecutive quarter, we demonstrated marked improvement in three key performance metrics; revenue growth, expense control and EBITDA. The result is that we have improved our cash position, while reducing the current liabilities without adding to the debt obligations of the Company. We continue to see consistent growth in the number of new customers added each quarter that will layer on top of our existing recurring revenue base. We expect our new customers to have an annual recurring duration of approximately eighteen years demonstrating the significant lifetime value of each new client," commented Joseph Vicente, President of Cord Blood America, Inc.

    The third quarter results also include a one-time charge for the sale of Stellacure GmbH as a Discontinued Operation on the Consolidated Statement of Operations, and are not included above the operating income (loss) line for year over year comparative purposes. As noted at the time of the announced sale of Stellacure, the realigned Company is stronger moving forward. Shedding the liabilities of Stellacure was also a key driver in improving the balance sheet of the Company by reversing a stockholder's deficit position at the end of 2011 of $.88 million to a stockholder equity position of $1.3 million; an improvement of $2.1 million in the nine month period.

    Mr. Vicente concluded, "We will continue to focus on the fundamentals of performance. We are confident this is the path to increasing shareholder value, while we also understand the urgency associated with this mission. We are confident in our strategy and we need to continue to deliver improved results."

    About Cord Blood America
    Cord Blood America, Inc. is the parent company of CorCell, Companies, Inc. which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. and CorCell Companies, Inc., visit our websites: http://www.cordblood-america.com/ for investor information and http://www.corcell.com/ for customer information.

    Forward-Looking Statements
    Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect,'' "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.Investor Contact:

    Cameron DonahueHayden IR(651) 653-1854cameron@haydenir.comWeb Site: http://www.cordblood-america.com


    '/>"/>
    SOURCE Cord Blood America, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related biology technology :

    1. FindTheBest Helps Parents Find Cord Blood Banks
    2. Cord Blood America Announces DTCC Removes "Chill" Imposed in December 2010
    3. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
    4. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
    5. Study finds chronic abnormal brain blood flow in Gulf War veterans
    6. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
    7. Cord Blood America Announces Exclusive Agreement With National Childrens Leukemia Foundation to Store Stem Cells
    8. Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development
    9. NxStage Extends Agreement to Supply Streamline Bloodlines, MasterGuard and Buttonhole Needle Technology to B. Braun
    10. Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
    11. Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/9/2016)... , December 9, 2016 According to a ... (Primer, Probe, Custom, Predesigned, Reagent Equipment), Application (Research, PCR, Gene, DNA, ... 2021" published by MarketsandMarkets, the global market is expected to reach ... at a CAGR of 10.6% during the forecast period. ... ...
    (Date:12/8/2016)... LONDON , Dec. 8, 2016 This report ... following Product Segments: Acid Based (Humic, Amino, & Fulvic), Extract ... by the following Crop Types: Ornamental & Turf, Row Crops, ... US, Canada , Japan ... , Latin America , and Rest of ...
    (Date:12/8/2016)... Dec. 8, 2016  OncoSec Medical Incorporated ("OncoSec") ... DNA-based intratumoral cancer immunotherapies, today announced financial results ... "We are delivering on our commitment to ... ImmunoPulse® IL-12. We are pleased with the early ... trial, and we are focused on advancing our ...
    (Date:12/8/2016)... India , December 8, 2016 ... a comprehensive analysis, titled Global Amyloglucosidase Industry 2016 Market Research ... classification, application, and industry chain overview are all covered in ... SWOT analysis, and investment return analysis of the Amyloglucosidase industry. ... , , ...
    Breaking Biology Technology:
    (Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
    (Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
    (Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
    Breaking Biology News(10 mins):